PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 65 | 2 | 333-340
Article title

The associations between the growth hormone/insulin-like growth factor-1 axis, adiponectin, resistin and metabolic profile in children with growth hormone deficiency before and during growth hormone treatment

Content
Title variants
Languages of publication
EN
Abstracts
EN
This study investigated associations between the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, adiponectin, resistin and metabolic profile in 47 GH-deficient children before and during 12 months of GH treatment. 23 short age-matched children without growth hormone deficiency (GHD) or any genetic or chronic disorders were recruited as controls at baseline. Metabolic evaluation included measurements of adiponectin, resistin, IGF-1, total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), glucose, insulin, glycated haemoglobin (HbA1c), thyroid stimulating hormone (TSH) and free thyroxine (free T4) concentrations. The GH-deficient children had significantly higher adiponectin (p<0.05) and total cholesterol (p<0.05) levels, and a significantly lower level of resistin (p<0.05) than the controls. Resistin at 6 months of GH treatment significantly correlated with changes in height SDS in that period (r=0.35) and with the level of fasting insulin (r=0.50), the HOMA-IR (r=0.56) and the QUICKI (r=-0.53) at 12 months of therapy. Adiponectin level at 12 months of GH treatment was significantly associated with changes in HDL-C within the first 6 (r=0.73) and within 12 (r=0.56) months of therapy, while resistin significantly correlated with an increment in IGF-1 within 12 months of treatment (r=0.49) and with total-C at 12 months (r=0.56). Untreated GH-deficient children had higher adiponectin and lower resistin levels than healthy short children without GHD. Adiponectin and resistin levels did not change significantly during the first 12 months of GH therapy. Good responders to GH treatment had a tendency for higher resistin level during GH therapy, which positively correlates with the insulin resistance parameters.
Year
Volume
65
Issue
2
Pages
333-340
Physical description
Dates
published
2018
received
2018-04-03
revised
2018-05-10
accepted
2018-05-10
(unknown)
2018-06-18
Contributors
  • Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland
  • Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland
  • Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland
author
  • Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland
author
  • Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland
References
  • Andersson B, Carlsson LM, Carlsson B, Albertsson-Wikland K, Bjarnason R, Swedish Study Group for Growth Hormone Treatment (2009) Decrease in adiponectin levels correlates to growth response in growth hormone-treated children. Horm Res 71: 213-218.doi: 10.1159/000201110.
  • Berryman DE, List EO, Sackmann-Sala L, Lubbers E, Munn R, Kopchick JJ (2011) Growth hormone and adipose tissue: beyond the adipocyte. Growth Horm IGF Res 21: 113-123.doi: 10.1016/j.ghir.2011.03.002.
  • Berryman DE, List EO (2017) Growth hormone's effect on adipose tissue: quality versus quantity. Int J Mol Sci 18: E1621.doi: 10.3390/ijms18081621.
  • Capalbo D, Esposito A, Di Mase R, Barbieri F, Parenti G, Vajro P, Pignata C, Salerno M (2012) Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol 37: 379-389.
  • Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Galluzzo A, D'Acquisto G, Giordano C (2007) Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 156: 353-360.doi: 10.1530/eje.1.02343.
  • Ciresi A, Pizzolanti G, Leotta M, Guarnotta V, Teresi G, Giordano C (2016) Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children. J Endocrinol Invest 39: 1023-1030.doi: 10.1007/s40618-016-0475-z.
  • Codoñer-Franch P, Alonso-Iglesias E (2015) Resistin: insulin resistance to malignancy. Clin Chim Acta 438: 46-54.doi: 10.1016/j.cca.2014.07.043.
  • Decker R, Albertsson-Wikland K, Kriström B, Nierop AF, Gustafsson J, Bosaeus I, Fors H, Hochberg Z, Dahlgren J (2010) Metabolic outcome of GH treatment in prepubertal short children with and without classical GH deficiency. Clin Endocrinol (Oxf) 73: 346-354.doi: 10.1111/j.1365-2265.2010.03812.x.
  • Fagerberg B, Fagerlund C, Hulthe J (2006) Resistin and GFR. Kidney Int 70: 1371.doi: 10.1038/sj.ki.5001583.
  • Filková M, Haluzík M, Gay S, Šenolt L (2009) The role of resistin as a regulator of inflammation: implications for various human pathologies. Clinical Immunology 133: 157-170.doi: 10.1016/j.clim.2009.07.013.
  • Foster C, Burton A, Scholl J, Scott ML, Gunter V, McCormick K (2014) Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocrinol Metab 27: 909-914.doi: 10.1515/jpem-2013-0488.
  • Giavoli C, Profka E, Rodari G, Lania A, Beck-Peccoz P (2017) Focus on GH deficiency and thyroid function. Best Pract Res Clin Endocrinol Metab 31: 71-78.doi: 10.1016/j.beem.2017.02.003.
  • Gleeson H, Barreto ES, Salvatori R, Costa L, Oliveira CR, Pereira RM, Clayton P, Aguiar-Oliveira MH (2007) Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol (Oxf) 66: 466-474.doi: 10.1111/j.1365-2265.2007.02753.x.
  • Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist, ed 2. Stanford University Press. Stanford, California.
  • Gualillo O, González-Juanatey JR, Lago F (2007) The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 17: 275-283.doi: 10.1016/j.tcm.2007.09.005.
  • Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR (2004) Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89: 1844-1848.doi: 10.1210/jc.2003-031410.
  • Housa D, Housová J, Vernerová Z, Haluzík M (2006) Adipocytokines and cancer. Physiol Res 55: 233-244.
  • Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 10: 1-5.doi: 10.1038/oby.2002.1.
  • Isgaard J, Arcopinto M, Karason K, Cittadini A (2015) GH and the cardiovascular system: an update on a topic at heart. Endocrine 48: 25-35.doi: 10.1007/s12020-014-0327-6.
  • Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309: 286-290.doi: 10.1016/j.bbrc.2003.07.003.
  • Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556.doi: 10.1210/jc.2004-0395.
  • Kim KW, Shin YH, Lee KE, Kim ES, Sohn MH, Kim KE (2008) Relationship between adipokines and manifestation of childhood asthma. Pediatr Allergy Immunol 19: 535-540.doi: 10.1111/j.1399-3038.2007.00690.x.
  • Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, Parhofer KG, Göke B, Broedl UC (2007) Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 19: 1070-1074.doi: 10.1097/MEG.0b013e3282f16251.
  • Kuromaru R, Kohno H, Ueyama N, Hassan HM, Honda S, Hara T (1999) Long-term effect of growth hormone (GH) treatment on body composition in children with GH deficiency. Endocr J 46 (Suppl): S35-S38.
  • Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R (2001) Cardiac mass and function, carotid artery intima-media thickness and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 86: 1061-1065.doi: 10.1210/jcem.86.3.7268.
  • Leczenie niskorosłych dzieci z somatropinową niedoczynnością przysadki (ICD10 E23) hormonem wzrostu. Obwieszczenie Ministra Zdrowia z dnia 26 sierpnia 2015 r. w sprawie wykazu refundo­wanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Dz. Urz. Min. Zdrow., 2015; 42: zał. B.19 (in Polish)
  • López-Siguero JP, López-Canti LF, Espino R, Caro E, Fernández-García JM, Gutiérrez-Macías A, Rial JM, Lechuga JL, Macías F, Martínez-Aedo MJ, Rico S, Rodríguez I, Guillén J, Arroyo FJ, Bernal S, Espigares R, Núñez M, Escribano A, Barrionuevo JL, Gentil J, Barrios V, Fernández-Nistal A, Martos-Moreno GA, Martínez V, Argente J (2011) Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-α and ghrelin levels in growth hormone-deficient children. J Endocrinol Invest 34: 300-306.doi: 10.3275/7169.
  • Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737.doi: 10.1038/nm724.
  • Matusik P, Klesiewicz M, Klos K, Stasiulewicz M, Barylak A, Nazarkiewicz P, Malecka-Tendera E (2016) Baseline body composition in prepubertal short stature children with severe and moderate growth hormone deficiency. Int J Endocrinol 4563721.doi: 10.1155/2016/4563721.
  • Meazza C, Elsedfy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M (2014) Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res 46: 219-223.doi: 10.1055/s-0033-1358730.
  • Møller N, Jørgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30: 152-177.doi: 10.1210/er.2008-0027.
  • Nozue H, Kamoda T, Matsui A (2007) Serum resistin concentrations in growth hormone-deficient children during growth hormone replacement therapy. Metabolism 56: 1514-1517.doi: 10.1016/j.metabol.2007.06.018.
  • Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H (2005) Prolactin and growth hormone regulated adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331: 1120-1126.doi: 10.1016/j.bbrc.2005.04.026.
  • Orrù S, Nigro E, Mandola A, Alfieri A, Buono P, Daniele A, Mancini A, Imperlini E (2017) A functional interplay between IGF-1 and adiponectin. Int J Mol Sci 18: E2145.doi: 10.3390/ijms18102145.
  • Oświęcimska JM, Roczniak W, Roczniak RG, Malczyk Z, Chyra M, Mazur B, Ziora KT (2017) Serum adiponectin levels in adolescents and young adults with growth hormone deficiency. Neuro Endocrinol Lett 38: 107-116.
  • Palczewska I, Niedźwiecka Z (2001) Wskaźniki rozwoju somatycznego dzieci i młodzieży warszawskiej. Med Wieku Rozwoj 5 (Suppl 1): 1-120 (in Polish)
  • Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300: 472-476.doi: 10.1016/S0006-291X(02)02841-3.
  • Reinehr T, Roth C, Menke T, Andler W (2004) Adiponectin before and after weight loss in obese children. J Clin Endocrinol Metab 89: 3790-3794.doi: 10.1210/jc.2003-031925.
  • Ronti T, Lupattelli G, Mannarino E (2006) The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64: 355-365.doi: 10.1111/j.1365-2265.2006.02474.x.
  • Rothermel J, Reinehr T (2016) Metabolic alterations in paediatric GH deficiency. Best Pract Res Clin Endocrinol Metab 30: 757-770.doi: 10.1016/j.beem.2016.11.004.
  • Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo D, Spinelli L, Muzzica S, Lombardi G, Colao A (2006) Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after 2 years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab 91: 1288-1295.doi: 10.1210/jc.2005-0981.
  • Sas T, Mulder P, Hokken-Koelega A (2000) Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 85: 3786-3792.doi: 10.1210/jcem.85.10.6917.
  • Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749.doi: 10.1074/jbc.270.45.26746.
  • Šenolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D, Anderlová K, Müller-Ladner U, Pavelka K, Haluzík M (2007) Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 66: 458-463.doi: 10.1136/ard.2006.054734.
  • Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 149: 331-335.doi: 10.1530/eje.0.1490331.
  • Singh B, Saxena A (2010) Surrogate markers of insulin resistance: a review. World J Diabetes 1: 36-47.doi: 10.4239/wjd.v1.i2.36.
  • Smyczyńska J, Hilczer M, Stawerska R, Lewiński A (2010) Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy - clinical implications. Thyroid Research 3: 2.doi: 10.1186/1756-6614-3-2.
  • Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226-228.doi: 10.1016/S0140-6736(03)12255-6.
  • Stawerska R, Smyczyńska J, Hilczer M, Lewiński A (2017) Relationship between IGF-I concentration and metabolic profile in children with growth hormone deficiency: the influence of children's nutritional state as well as the ghrelin, leptin, adiponectin, and resistin serum concentrations. Int J Endocrinol 5713249.doi: 10.1155/2017/5713249.
  • Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA (2002) Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 87: 4652-4656.doi: 10.1210/jc.2002-020694.
  • Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409: 307-312.doi: 10.1038/35053000.
  • Tanner JM (1962) Growth at adolescence, 2 edn. Oxford, Blackwell.
  • Trayhurn P, Bing C, Wood IS (2006) Adipose tissue and adipokines-energy regulation from the human perspective. J Nutr 136 (Suppl 7): 1935S-1939S.doi: 10.1093/jn/136.7.1935S.
  • van der Sluis IM, Boot AM, Hop WC, De Rijke YB, Krenning EP, de Muinck Keizer-Schrama SM (2002) Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm Res 58: 207-214.doi: 10.1159/000066262.
  • Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D (2010) Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 20: 1-7.doi: 10.1016/j.ghir.2009.09.002.
  • Wei T, Ye P, Peng X, Wu LL, Yu GY (2016) Circulating adiponectin levels in various malignancies: An updated meta-analysis of 107 studies. Oncotarget 7: 48671-48691.doi: 10.18632/oncotarget.8932.
  • Willemsen RH, van Dijk M, de Rijke YB, van Toorenenbergen AW, Mulder PG, Hokken-Koelega AC (2007) Effect of growth hormone therapy on serum adiponectin and resistin levels in short, small-for-gestational-age children and associations with cardiovascular risk parameters. J Clin Endocrinol Metab 92: 117-123.doi: 10.1210/jc.2006-0852.
  • Yannakoulia M, Yiannakouris N, Blüher S, Matalas AL, Klimis-Zacas D, Mantzoros CS (2003) Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88: 1730-1736.doi: 10.1210/jc.2002-021604.
  • Zhang JL, Qin YW, Zheng X, Qiu JL, Zou DJ (2003) Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 20: 828-831.doi: 10.1046/j.1464-5491.2003.01057.x.
  • Zou CC, Liang L, Hong F, Fu JF, Zhao ZY (2005) Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 52: 519-524.doi: 10.1507/endocrj.52.519.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv65p333kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.